It is an article of faith in oncology that cancer risk and aggressiveness increase with age. The older the patient, the reasoning goes, the more time mutations have accumulated and the more worn the immune system becomes. But epidemiologists have long noticed something odd: overall cancer incidence and metastatic spread do not rise linearly into the oldest ages. After roughly age 80, the rate of new diagnoses and aggressive disease flattens or even declines.
A new study presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting offers a mechanistic explanation — and it has less to do with the cancer cells themselves than with a little-known arm of the immune system that shifts dramatically across the lifespan.
Important caveat: The findings, presented as Abstract 2072 and published in the AACR meeting proceedings in Cancer Research, have not yet appeared in a peer-reviewed journal. The results are preliminary and based on mouse models; human data are not yet available.
The γδ T-cell U-shape
Working in mouse models of melanoma, a team led by Mitchell Fane, PhD, at the Fox Chase Cancer Center (Temple University Health System, Philadelphia) compared cancer spread across three age groups: young mice (equivalent to roughly human 20s), middle-aged mice (~40–50s), and very old mice (~70–85+).
What they found was not a straight line. Tumours in young mice spread the least. In middle-aged mice, metastasis to the lungs and liver was dramatically higher. In very old mice, it dropped back down.
The clue to why lay in a subset of immune cells called gamma delta (γδ) T-cells — a specialized population that sits at the boundary between the innate and adaptive immune systems, patrolling tissues for signs of stress or malignancy.
γδ T-cell levels followed the same U-shaped pattern as metastasis risk — but inverted:
- Young mice: High γδ T-cell numbers → low metastasis
- Middle-aged mice: Low γδ T-cell numbers → peak metastasis
- Very old mice: High γδ T-cell numbers again → metastasis recedes
“We found that γδ T-cell levels change with age in a way that tracks almost perfectly with metastatic risk,” Fane said. The implication is that these cells, not the cancer cells’ intrinsic aggressiveness, may be the dominant factor determining whether a tumour spreads.
PROS1: the cancer’s immune-suppression lever
The team also identified a molecular mechanism behind the age-dependent vulnerability. Melanoma cells secrete a signaling molecule called PROS1 that actively suppresses and exhausts γδ T-cells. This suppression was most effective in middle-aged mice, when γδ T-cell numbers were already at their lowest and the remaining cells were most vulnerable to exhaustion.
Causal experiments strengthened the case. When the researchers depleted γδ T-cells from young and very old mice, melanoma spread increased significantly — confirming that these cells were actively protective in those age groups. Conversely, blocking the PROS1 signaling pathway restored immune protection and reduced metastasis, but only in middle-aged mice.
The work builds on Fane’s earlier research, including a 2020 review in Nature Reviews Cancer (cited over 900 times) on how the ageing microenvironment influences tumour progression, written during his time at the Johns Hopkins Bloomberg School of Public Health under Ashani Weeraratna, a leading authority on ageing and melanoma.
Why this matters — and why caution is needed
If the pattern holds in humans, it challenges a deeply embedded assumption in oncology: that the oldest patients are always at highest risk for aggressive disease. Instead, the study suggests that middle-aged patients (roughly 40–65) may be at the greatest risk for melanoma metastasis — precisely because their γδ T-cell defences are at their lowest ebb.
The finding also opens a potential therapeutic avenue. PROS1 inhibitors or γδ T-cell-boosting strategies could, in principle, be used to reduce metastatic risk in middle-aged patients. Fane and colleague Yash Chhabra, PhD, have established an aged mouse facility at Fox Chase specifically to support this kind of research — a response to the fact that fewer than 10% of preclinical cancer studies use aged animal models.
But several critical limitations must be acknowledged:
- This is not a peer-reviewed paper. The findings were presented as a conference abstract at AACR 2026. They have been reviewed for presentation but not subjected to the full peer-review process required for journal publication.
- Mouse model only. The results come from melanoma cell lines implanted in mice. Whether human γδ T-cell behavior follows the same age pattern — and whether PROS1 inhibition would work in human patients — remains to be tested.
- Single cancer type. The study examined melanoma. The γδ T-cell mechanism may not generalize to other cancers.
- Single institution. The findings need independent replication.
- Quantitative details are limited. Exact effect sizes, p-values, and sample sizes from the abstract have not been published at the level of detail expected in a full manuscript.
Fane’s group has indicated a full manuscript is in preparation.
The sober bottom line
The observation that metastatic risk follows a U-shaped curve across age, coupled with a plausible immune mechanism (γδ T-cell depletion driven by PROS1-mediated suppression), is a genuinely interesting hypothesis. If confirmed, it would reshape how oncologists think about age and cancer aggressiveness and could lead to new strategies for preventing metastasis in middle-aged patients — the demographic with the highest melanoma burden.
But “if confirmed” is the operative phrase. Conference abstracts, by design, present preliminary results. The field will need to see these data survive peer review, replicate in human tissues, and generalize across cancer types before clinical recommendations change. For now, the study is a provocative reminder that ageing is not a monotonic process — and neither is the immune system’s ability to fight cancer.
Source:
- Coutant K, Price C, Pasamonte J, Datt P, Fane M. “Abstract 2072: Role of the aging on the γδ T-cells in metastatic cutaneous melanoma progression.” Cancer Research 2026; 86(7_Supplement): 2072. DOI: 10.1158/1538-7445.AM2026-2072. Presented at AACR 2026 Annual Meeting, April 2026.
- Fox Chase Cancer Center press release, April 17, 2026.
- ScienceDaily, May 30, 2026.